Health Care·Biotechnology·$3.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.79 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.79 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the company's progress and emphasized their commitment to advancing their drug development pipeline.
We are pleased with our progress in the quarter.
Our focus remains on advancing our pipeline.
Denali Therapeutics' earnings report showed a solid EPS figure, although revenue details were not disclosed. The stock reacted positively, rising 1.79%, likely due to the company's progress in its drug development efforts. Investors may be encouraged by management's optimistic tone regarding future advancements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ZTO EXPRESS CAYMAN I Class A ADR
Mar 12, 2019